Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma. http://www.worldpharmanews.com/amgen/3608-amgen-obtains-global-development-and-commercial-rights-from-boehringer-ingelheim-for-investigational-bite-immuno-oncology-drug-for-multiple-myeloma